1. Executive Summary
2. Research Methodology
3. Migraine
3.1 Overview
3.1.1 Types of Migraine
3.1.2 Stages of Migraine
3.1.3 Symptoms of Migraine
3.1.4 Diagnosis
3.2 Treatment
3.2.1 Abortive Medications
3.2.2 Preventive Medications
3.2.3 Alternative Medicine
4. Market Analysis
4.1.1 Market Sizing (Actual & Forecasted)
4.2 Market Share Analysis
4.2.1 Market Share by Treatment Drugs
4.2.2 Market Share by Drug Type
4.2.3 Market Share by Nations
5. Market Segmentation by Drug Class
5.1 Triptan
5.1.1 Overview
5.1.2 Market Sizing (Actual & Forecasted)
5.2 CGRP
5.2.1 Overview
5.2.2 Market Sizing (Actual & Forecasted)
5.3 Acetylcholine Inhibitors/ Neurotoxins
5.3.1 Overview
5.3.2 Market Sizing (Actual & Forecasted)
5.4 Others
5.4.1 Overview
5.4.2 Market Sizing (Actual & Forecasted)
6. Migraine Market Regional Analysis
6.1 North America
6.1.1 The US
6.1.1.1 Market Sizing (Actual & Forecasted)
6.2 Europe
6.2.1 France
6.2.1.1 Market Sizing (Actual & Forecasted)
6.2.2 Germany
6.2.2.1 Market Sizing (Actual & Forecasted)
6.2.3 Italy
6.2.3.1 Market Sizing (Actual & Forecasted)
6.2.4 Spain
6.2.4.1 Market Sizing (Actual & Forecasted)
6.2.5 The UK
6.2.5.1 Market Sizing (Actual & Forecasted)
6.3 Asia Pacific
6.3.1 Japan
6.3.1.1 Market Sizing (Actual & Forecasted)
7. Market Dynamics
7.1 Industry Trends & Development
7.1.1 Anti-CGRP Drugs Pipeline
7.1.2 Launch of Cheaper Migraine Drugs
7.1.3 Emphasis on Preventative Migraine Treatment
7.1.4 Advent of Novel Migraine Drugs
7.1.5 Neuromodulation Devices for Migraine Treatment
7.2 Growth Drivers
7.2.1 Prevalence of Migraine
7.2.2 Rising Female Population
7.2.3 Patent Expirations
7.2.4 Stressed Lifestyle
7.3 Challenges
7.3.1 Poor Efficacy of Drugs
7.3.2 Regulatory Hurdle
7.3.3 Low Diagnosis Rate
7.3.4 Preference for Alternative Therapies
8. Competitive Landscape
9. Company Profile
9.1 Eli Lilly & Company
9.2 Teva Pharmaceutical Industries
9.3 Alder Biopharmaceuticals
9.4 Amgen Inc.
9.5 AbbVie Inc.
9.6 Pfizer Inc.